2023-12-12 09:42:28 ET
A Massachusetts-based %Biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that it has entered into an exclusive license and collaboration agreement with Merck (known as MSD outside of the U.S. and Canada) to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells, according to the release.
Traders were extremely optimistic on the news as shares of %C4Therapeutics (Nasdaq: CCCC) are currently bid up at $1.75/share (+48.31% implied open for sellers) at the time of writing. This should be an exciting session for this micro cap.
C4 Therapeutics Inc (Nasdaq: $CCCC) is a bio-pharmaceutical company. The company is focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of C4 Therapeutics Inc. (CCCC) and does not buy, sell, or trade any shares of (CCCC). This article does not provide a professional analysis of a (CCCC) financial position. (CCCC) financial position and all other information regarding the featured Company should be verified directly with (CCCC). Please read our full disclaimer for more detailed information.
